"Precigen (PGEN) recently received FDA approval for its immunotherapy, PAPZIMEOS, marking a significant milestone as the first approved treatment for adults with recurrent respiratory papillomatosis. While this approval serves as a positive catalyst for the company, risks remain regarding market adoption and the overall commercial viability of the therapy, contributing to a cautious sentiment reflected in the average sentiment score of 0.35."